SOPHIA ANTIPOLIS CEDEX, FRANCE--(Marketwire - April 02, 2012) -
April 2, 2012. Sophia Antipolis, France. www.nicox.com
NicOx S.A. (NYSE Euronext Paris: COX) today announces the appointment
Philippe Masquida as Executive Vice President, Managing Director of
Operations. Mr. Masquida has over 22 years of senior
pharmaceutical experience and an impressive track record in ophthalmology.
Mr. Masquida will lead NicOx's operations in Europe and in this role he
managing the European subsidiaries. In addition he will be
coordination with the executive team of NicOx, for identifying and
commercial opportunities in Europe as part of the Company's strategy to
late-stage ophthalmic portfolio. He will be part of NicOx's Executive
and report to Michele Garufi, Chairman and CEO.
Mr. Masquida joins NicOx from Pierre Fabre where he was Vice President,
International Operations, Pharmaceuticals, and was responsible for 25
in Europe, Asia, Americas, Middle East and Africa, employing around
people. Prior to this he spent 7 years at Allergan Inc., where he
led the growth of the Company's Emerging Markets in Europe, Africa
Middle East, including in ophthalmology. He also held the position of
of International Affairs for 8 years at Laboratoires Théa, an
pharmaceutical company specialized in ophthalmology, where he was
in the establishment of a number of European subsidiaries and was
for international business. Mr. Masquida has previously held a
positions at Sanofi Aventis (Fisons) and Merck Inc.
On March 21, 2012, NicOx announced a strategy to create an international,
late-stage development and commercial ophthalmology company
therapeutics, diagnostics and devices. The appointment of Mr. Masquida is
part of this strategy and follows the appointment of Jerry St. Peter
United States. As a first step in this transformation, NicOx has acquired
of the shares of Altacor, a privately-held ophthalmology company based
United Kingdom, and entered into an exclusive option agreement to
remaining shares of Altacor. NicOx has a number of other opportunities
under discussion which could lead to additional M&A or in-licensing to
balanced ophthalmology pipeline across the United States and Europe.
Michele Garufi, Chairman and CEO of NicOx, said: "The appointment of
Masquida is another significant step forward in our strategy to
international late-stage development and commercial ophthalmology
brings a wealth of business management skills and extensive
Ophthalmology, which will be of significant value as we continue to
diverse late-stage portfolio in ophthalmology with a clear
Philippe Masquida commented: "The ophthalmology market is
significant growth and there is a real opportunity for NicOx to
international, mid-sized player to occupy the space between big pharma and
players. With its existing expertise and clear growth strategy, I believe
is well placed to take full advantage of these opportunities and I look
to working with the team as we create a global ophthalmology company."
NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is building an international
late-stage development and commercial Ophthalmology Company based around
therapeutics, diagnostics and devices. As of March 2012, NicOx holds an
stake in the UK-based ophthalmology company Altacor, with an option to
the remaining shares, as the first step of a transformation into a
late-stage development and commercial ophthalmic Company.
NicOx is also developing an internal portfolio of New Molecular Entities
through the application of its proprietary nitric oxide-donating R&D
platform. The Company's pipeline includes several nitric oxide-donating
the potential treatment of ophthalmological, inflammatory and
cardio-metabolic diseases, which are in development internally and with
include Bausch + Lomb, Merck (known as MSD outside theUnited States
NicOx S.A. is headquartered in France and is listed on Euronext Paris
(Compartment C: Small Caps).
This press release contains certain forward-looking statements. Although
Company believes its expectations are based on reasonable assumptions,
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
the forward-looking statements.
Risks factors which are likely to have a material effect on NicOx's
presented in the 4(th) chapter of the « Document de
référence, rapport financier
annuel et rapport de gestion 2011 » filed with the French
Autorité des Marchés
Financiers (AMF) on February 29, 2012 and available on NicOx's
(www.nicox.com) and on the AMF's website (www.amf-france.org).
Les Taissounières - Bât HB4 - 1681 route des Dolines - BP313 -
Antipolis Cedex - France
Tel: +33 (0)4 97 24 53 00 • Fax: +33 (0)4 97 24 53 99
NicOx appoints Philippe Masquida EVP, Managing Director of European Op:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: NICOX via Thomson Reuters ONE